A push to require doctors to treat unvaccinated patients fell short on the final day of  the Florida Legislature’s regular ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

The U.S. Health and Human Services Department says it will require placebo testing of "all new vaccines," raising questions ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

Clinical trials for the NIH's new universal flu vaccine are anticipated by 2026, with FDA approval by 2029. Other viruses like COVID and bird flu will follow.

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

The agency suggested that clinical trials in humans may be required for updated Covid shots, raising questions about whether ...

Vaccines save millions of lives every year, but there is still an urgent need for more efficient vaccines. Strategies to combat serious outbreaks of viral infections are particularly important. Such ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.